Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Epizyme Inc (NQ: EPZM )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Epizyme Inc

< Previous 1 2 3 4 5 Next >
Epizyme Raises $85M Via Equity Issued At 21% Discount
Epizyme Inc (NASDAQ: EPZM) has priced its underwritten public offering of 56.7 million shares at  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock increased by 28.7% to $2.24 during Thursday's pre-market session. The company's market cap stands at $31.4... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're starting off the day with an overview of the biggest pre-market stock movers to watch on Thursday! 
Via InvestorPlace
26 Stocks Moving in Thursday's Pre-Market Session
Gainers The National Security Group, Inc. (NASDAQ: NSEC) rose 63.7% to $15.10 in pre-market trading after VR Insurance Holdings announced acquisition of The National... 
Via Benzinga
Epizyme Announces Pricing of Public Offering of Common Stock
From Epizyme, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Reneo Pharmaceuticals (NASDAQ:RPHM 
Via Benzinga
Epizyme Announces Proposed Public Offering of Common Stock
From Epizyme, Inc.
Via Business Wire
Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates
From Epizyme, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a... 
Via Benzinga
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting
From Epizyme, Inc.
Via Business Wire
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting
From Epizyme, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Quoin Pharmaceuticals (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Updates to Its Board of Directors
From Epizyme, Inc.
Via Business Wire
Epizyme to Participate in Jefferies London Healthcare Conference
From Epizyme, Inc.
Via Business Wire
Epizyme's Return On Capital Employed Insights
Benzinga Pro data, Epizyme (NASDAQ:EPZM) reported Q3 sales of $5.20 million. Earnings fell to a loss of $64.16 million, resulting in a 10.09% decrease from last quarter. In Q2,... 
Via Benzinga
Epizyme, inc (EPZM) Q3 2021 Earnings Call Transcript
EPZM earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414
From Epizyme, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Epizyme Announces Date of Third Quarter 2021 Financial Results
From Epizyme, Inc.
Via Business Wire
Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress
From Epizyme, Inc.
Via Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.